Patents by Inventor Michael A. Kauffman

Michael A. Kauffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6693598
    Abstract: An omni-directional antenna assembly is provided for wireless communication devices requiring multiple polarization characteristics. A loop antenna assembly for a communications device operating at a predetermined wavelength and having a transceiver circuit including a signal output and a ground plane, the antenna assembly including a conductive loop element and a conductive leg member coupled to the loop element proximate a loop perimeter, the leg member for supporting the loop element at a distance away from the ground plane of the communications device, the leg member also defining a ground point and a feed point for operatively coupling the loop element to the ground plane and the signal output, respectively, of the transceiver circuit.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: February 17, 2004
    Assignee: Tyco Electronics Logistics AG
    Inventors: Bruce Bishop, Matthew H. Commens, Patrick McKivergan, Kevin Ketelsen, Ben Newman, Michael A. Kauffman, Jerry Hovey
  • Publication number: 20020119150
    Abstract: Compositions and methods disclosed herein capitalize on the discovery that rejection of a tissue graft can be inhibited using a CD40:CD154 binding interrupter, either alone or in combination with another immunomodulator or immunosuppressor. An advantageous, synergistic combination includes a CD40:CD154 binding interrupter and a CD28 signaling interrupter. An exemplary CD40:CD154 binding interrupter is an anti-CD154 monoclonal antibody, such as an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody. An exemplary CD28 signaling interrupter is a CTLA4-Ig fusion protein. The disclosed compositions and methods unexpectedly can be used to prolong survival of grafted tissue in a recipient host, to reverse acute graft rejection, and to attenuate immunological consequences of the failure of grafted tissue.
    Type: Application
    Filed: April 9, 2002
    Publication date: August 29, 2002
    Applicant: United States of America as represented by the Secretary of the Navy and Biogen, Inc.
    Inventors: Allan D. Kirk, David M. Harlan, David W. Thomas, Michael Kauffman, Linda Burkly